Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trialopen access
- Authors
- Hong, D.[Hong, D.]; Shergill, A.[Shergill, A.]; Bazhenova, L.[Bazhenova, L.]; Cho, B.C.[Cho, B.C.]; Heist, R.[Heist, R.]; Moreno, V.[Moreno, V.]; Falchook, G.S.[Falchook, G.S.]; Nagasaka, M.[Nagasaka, M.]; Cassier, P.[Cassier, P.]; Besse, B.[Besse, B.]; Kim, D.W.[Kim, D.W.]; Yoon, S.[Yoon, S.]; Le, X.[Le, X.]; Zhao, T.[Zhao, T.]; Atwal, S.[Atwal, S.]; Park, E.[Park, E.]; Lee, J.[Lee, J.]
- Issue Date
- Oct-2022
- Publisher
- Elsevier Ltd
- Citation
- European Journal of Cancer, v.174, pp.S72
- Indexed
- SCIE
SCOPUS
- Journal Title
- European Journal of Cancer
- Volume
- 174
- Start Page
- S72
- ISSN
- 0959-8049
- Abstract
- [No abstract available]
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.